CEDAR

Scientific Reference

GLOW Stack (GHK-Cu + TB-500 + BPC-157)

Evidence profile: Component evidence only — this formulation has not itself been studied

The GLOW Protocol is a three-peptide regenerative blend combining GHK-Cu, TB-500 (Thymosin Beta-4), and BPC-157. It is designed as a multi-pathway approach to tissue repair, collagen synthesis, and cellular regeneration, with a particular focus on skin and connective tissue.\n\nTypical formulations contain approximately 50mg GHK-Cu, 10mg TB-500, and 10mg BPC-157 in a 5:1:1 ratio. While individual peptides have established research backgrounds, no clinical trials have evaluated this specific combination, and all effects remain theoretical based on additive and complementary mechanisms.

Mechanism of Action

The GLOW Protocol integrates three complementary mechanisms: GHK-Cu modulates gene expression and stimulates collagen synthesis; TB-500 enhances cell migration and cytoskeletal repair; and BPC-157 promotes angiogenesis and growth factor signalling. Together, these pathways aim to support coordinated tissue regeneration and extracellular matrix remodelling, though this combination has not been clinically validated.

Molecular Information

  • Type: Multi-peptide protocol

Published Research

  • RGN-259 neurotrophic keratopathy phase III

    0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

    Sosne G et al. · International journal of molecular sciences · 2022 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 36613994 — View on PubMed

  • The effect of thymosin treatment of venous ulcers

    Guarnera G et al. · Annals of the New York Academy of Sciences · 2010 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 20536470 — View on PubMed

  • A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

    Ruff D et al. · Annals of the New York Academy of Sciences · 2010 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 20536472 — View on PubMed

  • Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

    Miller TR et al. · Archives of facial plastic surgery · 2006 · Clinical · Evidence for GHK-Cu

    PMID 16847171 — View on PubMed

  • A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

    Bishop JB et al. · Journal of vascular surgery · 1992 · Clinical · Evidence for GHK-Cu

    PMID 1495150 — View on PubMed

  • Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK et al. · The American journal of sports medicine · 2026 · Review · Evidence for BPC-157

    PMID 41476424 — View on PubMed